News
Videos
Conferences
Events
Resources
Subscribe

|Articles|October 1, 2014

Dana-Farber Leads Kadcyla ATEMPT Study in HER2-Positive Breast Cancer

Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.

Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.

Newsletter

Stay up to date on cancer updates, research and education

Related Content

The Emmy-winning journalist and author delivered the keynote address at the inaugural Blood Cancer Heroes event.

Suleika Jaouad Celebrates Blood Cancer Heroes With CURE and Blood Cancer United

BySuleika Jaouad

December 10th 2025

In a recent interview with CURE, Dr. Kai Tsao discussed treatment advancements for patients with prostate cancer.

Breaking Down the Prostate Cancer Treatment Renaissance

December 9th 2025

Dr. Robert Orlowski, chairman, Ad Interim; director of Myeloma; and professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston.

Single-Drug Approach Explored for Newly Diagnosed Multiple Myeloma

ByDr. Robert Orlowski

December 8th 2025

Image of man.

Real-Time Text Tool Tracks Quality of Life in Myeloma Care

ByDr. James Berenson

December 7th 2025

Dr. Thomas Marron explains how therapeutic vaccines differ from preventative vaccines in lung cancer care.

How Therapeutic Vaccines May Transform Lung Cancer Care

ByDr. Thomas Marron

December 5th 2025

Trending on CURE

Real-Time Text Tool Tracks Quality of Life in Myeloma Care

Breaking Down the Prostate Cancer Treatment Renaissance

A Closet Full of Boobs and the Thought That Caught Me by Surprise

Tecvayli Treatment Combo Improves Outcomes in Relapsed/Refractory Myeloma

New Data Support Pelabresib Combination in Untreated Myelofibrosis

© 2025 MJH Life Sciences^®

All rights reserved.